

PRELIMINARY AGENDA (SUBJECT TO CHANGE)

FRIDAY, NOVEMBER 6 - SATURDAY, NOVEMBER 7, 2026

DAY 1 - FRIDAY, NOVEMBER 6, 2026

12:00 PM - 01:00 PM Registration, Exhibits, & Lunch

01:00 PM - 01:15 PM Meeting Introduction

01:20 PM - 02:30 PM Session 1A: Applying Precision Therapy in the Adjuvant Setting - Stage IA p53 endometrial cancer

- 01:20 PM - 01:40 PM Molecular staging of endometrial cancer: approach to p53 abnormal tumors
- 01:40 PM - 02:00 PM A critical review of the role of radiation in early-stage endometrial cancer
- 02:00 PM - 02:15 PM Discussion
- 02:15 PM - 02:30 PM Panel Vote

02:30 PM - 02:45 PM BREAK & EXHIBITS

02:45 PM - 03:55 PM Session 1B: Applying Precision Therapy in the Adjuvant Setting - mBRCA-associated ovarian cancer (relapsed on PARP inhibitor)

- 02:45 PM - 03:05 PM Adjuvant PARP Inhibitors: Update on long-term benefit
- 03:05 PM - 03:25 PM Is there a role for PARPi after progression on a prior PARPi?
- 03:25 PM - 03:40 PM Discussion
- 03:40 PM - 03:55 PM Panel Vote

04:00 PM - 05:10 PM Session 2A: ADCs in Gynecologic Cancer - FOLR-positive platinum-resistant recurrent ovarian cancer

- 04:00 PM - 04:20 PM The current state of FOLR1 directed treatments: mirvetuximab and beyond
- 04:20 PM - 04:40 PM Emerging options for Plat-resistant ovarian cancer: going beyond FOLR positivity
- 04:40 PM - 04:55 PM Discussion
- 04:55 PM - 05:10 PM Panel Vote

DAY 2 - SATURDAY, NOVEMBER 7, 2026

07:00 AM - 08:00 AM Registration, Exhibits, & Breakfast

08:10 AM - 09:25 AM Session 2B: ADCs in Gynecologic Cancer - HER2+ Endometrial cancer previously treated with trastuzumab

- 08:10 AM - 08:30 AM The role of ADCs in endometrial cancer
- 08:30 AM - 08:50 AM Targeting HER2: is earlier better?
- 08:55 AM - 09:10 AM Discussion
- 09:10 AM - 09:25 AM Panel Vote

09:25 AM - 09:40 AM BREAK & EXHIBITS

09:40 AM - 11:45 AM SESSION 3 APPLYING PRECISION THERAPY IN THE ADJUVANT SETTING

09:40 AM - 10:20 AM 3A: Preferred treatment for patients with dMMR stage IIIC endometrial cancer

- 09:40 AM - 10:00 AM The role of checkpoint inhibitors in dMMR endometrial cancer
- 10:00 AM - 10:20 AM Options and endpoints with adjuvant RT for endometrial cancer

10:20 AM - 10:40 AM 3B: Preferred strategy post-surgery for patients with POLE stage IIIA endometrial cancer

- POLE-endometrial cancer: Does stage matter?

10:40 AM - 11:45 AM 3C: Treatment with immunotherapy for patients with cervical cancer

- 10:40 AM - 11:00 AM A critical evaluation of checkpoint inhibitors in cervical cancer: Are there biomarkers predicting response?
- 11:00 AM - 11:30 AM Discussion
- 11:30 AM - 11:45 AM Panel Vote

11:45 AM - 01:00 PM LUNCH & EXHIBITS

09:40 AM - 11:45 AM SESSION 4 CLINICAL EQUIPOISE IN GYNECOLOGIC CANCERS

01:00 PM - 01:20 PM Session 4A: Patients with newly diagnosed 2023 FIGO stage IC cervical cancer

- A look at primary treatment of cervical cancer: Making sense of clinical trials

01:20 PM - 01:40 PM Session 4B: Patients with Stage IV endometrial cancer due to peritoneal carcinomatosis

- The role of surgery in advanced/metastatic gynecologic cancers

01:40 PM - 02:45 PM Session 4C: Post-treatment for stage IIIC ovarian cancer

- 01:40 PM - 02:00 PM MRD monitoring in ovarian cancer: Time has come or not just yet?
- 02:00 PM - 02:30 PM Discussion
- 02:30 PM - 02:45 PM Panel Vote

02:45 PM - 03:00 PM BREAK & EXHIBITS

03:00 PM - 03:40 PM Session 5A: A critical review of pembrolizumab in ovarian cancer: KEYNOTE B96 - Emerging treatment in platinum-resistant ovarian cancer

03:40 PM - 04:45 PM Session 5B: Applying Precision Therapy in Gynecologic Cancer: Maintenance Strategies - metastatic cervical cancer with previous treatment of pembrolizumab with chemoradiation

03:40 PM - 04:00 PM Re-treatment with immune checkpoint inhibitors: what do we know?

- 04:00 PM - 04:30 PM Discussion
- 04:30 PM - 04:45 PM Panel Vote